California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Recruiting
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: Jonnsson Comprehensive Cancer Center / University of Los Angeles, Los Angeles, California
Conditions: Multiple Myeloma
Evaluation of the Performance and Acceptability of a Synthetic Polyisoprene Male Condom Compared to a Natural Rubber Latex Condom
Recruiting
This study is a masked (investigators, research staff), two-way crossover, randomized to sequence of use study designed to evaluate the acceptability and functional performance (breakage, slippage) of a silicone lubricated polyisoprene condom and a silicone lubricated natural rubber latex condom.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
09/11/2024
Locations: Essential Access, Berkeley, California
Conditions: Condom Use
Peripheral Bypass Trial for Completion Control
Recruiting
The goal of the study is to identify and validate flow measurement and ultrasound images in patients undergoing vein bypass surgery below-knee and above ankle
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: University of California, San Francisco, California
Conditions: Chronic Limb-Threatening Ischemia
Encore PFO Closure Device - The PerFOrm Trial
Recruiting
The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
09/11/2024
Locations: Southern CA Permanente Medical Group - Kaiser San Diego and Scripps Memorial Hospital, La Jolla, California
Conditions: Patent Foramen Ovale, Cryptogenic Stroke
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Recruiting
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Cushing Disease
Predicting Cognitive Decline From Androgen Deprivation Therapy
Recruiting
Androgen Deprivation Therapy (ADT) is associated with cognitive impairment and dementia in men with prostate cancer. Pre-clinical data suggest that ADT-induced hypogonadism leads to accumulation of beta-amyloid plaques in the hippocampus, a pathological hallmark of Alzheimer's Disease (AD). Neuroimaging Functional magnetic resonance imaging (fMRI) studies also demonstrate that ADT decreases metabolic activity in the parietal, occipital, and prefrontal cortices. Multiple prospective cohort and po... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Cancer
A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recruiting
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
UCSF PANC Cyst Registry
Recruiting
Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to pr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Cancer, Pancreatic Diseases, Pancreatic Ductal Adenocarcinoma, Mucinous Cyst, Pancreatic Intraductal Papillary Mucinous Neoplasm, Intraductal Papillary Mucinous Neoplasm
First In Human Study of CX-801 in Advanced Solid Tumors
Recruiting
The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: University of California San Francisco, San Francisco, California
Conditions: Solid Tumor, Adult
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Recruiting
This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax following an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day of DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews toxicity after one treatment cycle. If DLTs are minimal,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: UCI Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Leukemia, Myeloid, Acute
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
Recruiting
This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is being evaluated to provide an informal comparison of pharmacodynamic and clinical effects of concurrent dosing schedule.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Ellison Institute of Technology (EITM), Los Angeles, California
Conditions: Triple Negative Breast Cancer
Examining Bluetooth Haptic Device Use for Pain and Anxiety Reduction in Vascular Access Procedures
Recruiting
This pragmatic, randomized study seeks to evaluate the applications of a novel vibrating device for reducing pediatric anxiety and distress during vascular access procedures.
Gender:
ALL
Ages:
Between 4 years and 99 years
Trial Updated:
09/09/2024
Locations: Lucile Packard Childrens Hospital Stanford, Palo Alto, California
Conditions: Pain, Anxiety